| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Bruker's Stock Plunge An Over-reaction
Posted on 05/02/2007 19:22:31 | Link | Post Comment
by H.S. Ayoub
BioHealth Investor.com
Well, it seems that a comment I had made earlier, "Bear Stearns knows something, and it is making me nervous," might have been an over-reaction on my part. As much of an over-reaction as was seen on Wall Street Tuesday after Bruker BioSciences (BRKR) stock plunged more than 20% following a pretty decent earnings report.
It seems that Bear Stearns released an opinion report to its clients following the conference call saying that while earings were good, the stock is over-valued according to their valuation models.
The stock price sits at $9.08 as of noon Wednesday, still a decent gain from February's $7.70 stock offering, and a little lower than my entry point of $9.42.
Given the polarizing effects of the Bear Stearns report and the stock offering, it seems that Bruker's stock might hover in this $9 range for a while.
Source: BioHealth Investor.com
RELATED READING:
- Bruker's Profits Increase, So Why the 20% Drop?
- Bruker BioSciences: Earnings Growing, Insiders Buying
______________________
BioHealth Investor.com
Well, it seems that a comment I had made earlier, "Bear Stearns knows something, and it is making me nervous," might have been an over-reaction on my part. As much of an over-reaction as was seen on Wall Street Tuesday after Bruker BioSciences (BRKR) stock plunged more than 20% following a pretty decent earnings report.
It seems that Bear Stearns released an opinion report to its clients following the conference call saying that while earings were good, the stock is over-valued according to their valuation models.
The stock price sits at $9.08 as of noon Wednesday, still a decent gain from February's $7.70 stock offering, and a little lower than my entry point of $9.42.
Given the polarizing effects of the Bear Stearns report and the stock offering, it seems that Bruker's stock might hover in this $9 range for a while.
Source: BioHealth Investor.com
RELATED READING:
- Bruker's Profits Increase, So Why the 20% Drop?
- Bruker BioSciences: Earnings Growing, Insiders Buying
______________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- The Boston Condo Blog
- Millionaire Now! by Larry Nusbaum
- The Boston Real Estate Blog
- Biiwii.com Notes
- Investor Alert
- The Technical Trader
Examples
Morpheus Trading - Tue Sep 02, 2008 05:21AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Thu Sep 04, 2008 04:34AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Wed Sep 03, 2008 04:35AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
<< My Home | TheMoneyBlogs Home